Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jun 19, 2021 11:44am
170 Views
Post# 33416666

RE:RE:RE:RE:THTX’s short volume

RE:RE:RE:RE:THTX’s short volume Also, the more I think about it, the more they look like a company waiting for some certainty in oncology before officially starting their NASH phase III. It would make sense. Positive news in oncology would drive the stock price and allow to fully finance the NASH part of things at much more favourable conditions.

jfm1330 wrote: Don't expect what is impossible out of this presentation. The only new positive data they could bring is that the maximum tolerable dose is still not reached and that they are now over the MTD of free docetexel. They could also have pharmacokinetics data up to noe suggesting that the PDC is behaving the expected way. It would come through testing os free docetaxel in the blood over time after injection and the same for TH1902. Other than that, I don't see what new data on humans they could bring. That being said, maybe I am missing something. What is very unlikely, is some negative news concerning the trial. Why organizing such a presentation if it would be to disclose negative news? It does not make sense.


Lee430 wrote: Gonna be a long weekend waiting for the webinar or Great Rebrand, Pleeeease don't be another non event.

scarlet1967 wrote: Today about 170 k was traded in Nasdaq, the highest daily volume this week, short volum was 10.5% an increase from yesterday but far less than the median average. So most of the trades were buyers taking positions before Monday's webinar and sellers offloading as the price/volume increased to about monthly high.
Not enough price appreciation or volume to suspect a leak of information. It's everyone's guess what will be shared on Monday.

Date

Short Volume

Total Volume

(MM Shares)

US:THTX Short Volume Ratio

2021-06-18

17,805

0.17

10.5





scarlet1967 wrote: Today over 90k was traded in Nasdaq which was the highest daily volume this week, the short volume was 5.56% which was one of the lowest this week so maybe some started to take positions already prior to Monday's webinar? 
Also some pathetic after hours trading, only some 30 shares the latest trade to push the price down a little. Not as much volume as one would like to see prior to the event but better than previous trading days this week.

Time (ET)

After Hours Price

After Hours Share Volume

19:22:53

$3.54

6

19:22:53

$3.55

24

16:08:55

$3.6

7

Market Date

Short Volume

Total Volume

(MM Shares)

US:THTX Short Volume Ratio

2021-06-17

4,952

0.09

5.5


 

 




<< Previous
Bullboard Posts
Next >>